While Geron Corp. (NASDAQ:GERN) saw a big bounce back today after getting crushed last week, making it today's big winner in the biotech space, Galena Biopharma (NASDAQ:GALE) took it on the chin from the market, making it the loser of the day.

Shares of Geron came back 23% today, as hope of an FDA clinical hold on its key drug, imetelstat, may prove temporary. The hold was placed on the drug last week, which crushed shares of the stock. In this video, Motley Fool health-care analyst David Williamson looks at a compelling and bullish Seeking Alpha article that argues the case for why the hold might be temporary, but he warns that this is still a binary outcome investment, and that hoping for a pop if the hold is lifted could be more akin to gambling than investing.

While it was a great day for Geron investors, shares of Galena Biopharma took a big hit, down 12% because of SEC concerns regarding allegations of stock pumping. The SEC is investigating the company as well as an outside investor relation firm on the subject. David says he prefers to stay away from companies being scrutinized by the SEC, saying there are less controversial and better places to invest.

So where else can a growth investor look outside of the volatile biotech space?
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.